The FDA has approved application ANDA085964 for an oral tablet product named Acetaminophen and Codeine Phosphate.
The tablet contains 300 mg of acetaminophen and 60 mg of codeine phosphate per dose. It is marketed by Sandoz and is currently listed with a marketing status of discontinued.
Submission history includes an original submission (number 1) approved on 1978‑07‑18, followed by several supplemental labeling submissions (numbers 40, 42, 43, 44, 45) approved between 1988 and 1991.
The product is not designated as a reference drug and does not have a reference standard.
Regulatory UpdatesSep 5, 2026•1 min read
FDA Approves ANDA085964 for Acetaminophen and Codeine Phosphate Tablet
The FDA approved ANDA085964 for Sandoz's oral tablet containing 300 mg acetaminophen and 60 mg codeine phosphate; the product is listed as discontinued after multiple labeling submissions.
Compiled by the PharmaCountry team · Source: FDA.gov
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating